From: The effect of pegylated interferon-alpha2b and ribavirin combination therapy for chronic hepatitis C infection in elderly patients
Aged < 65 years group(n= 33)
Aged ≥ 65 years group(n= 15)
Anemia
9
5
Thrombopenia
3
General fatigue
7
Poor response to therapy
8
4